source
- China-origin biotech deals and IPOs surge as investors reap early returns, while Summit Therapeutics shares slumpBiotech firms built around medicines originating in China have accelerated both acquisitions and initial public offerings this year, according to recent data visualizations. The large pool of Chin…
- US panel warns China’s biotech plan could dominate sector and threaten drug supply chainA congressional commission has warned that China’s new five-year biotech plan could allow it to dominate the global drug market. The commission says the strategy could leave U.S. patients vulnerab…